"V体育官网入口" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Clinical Trial
. 2018 Dec;155(6):1741-1752.e5.
doi: 10.1053/j.gastro.2018.08.022. Epub 2018 Aug 23.

VSports手机版 - FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid

Affiliations
Clinical Trial

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid (V体育安卓版)

Elliot S Friedman (V体育2025版) et al. Gastroenterology. 2018 Dec.

Abstract

Background & aims: Intestinal bacteria can modify the composition of bile acids and bile acids, which are regulated by the farnesoid X receptor, affect the survival and growth of gut bacteria. We studied the effects of obeticholic acid (OCA), a bile acid analogue and farnesoid X receptor agonist, on the intestinal microbiomes of humans and mice. VSports手机版.

Methods: We performed a phase I study in 24 healthy volunteers given OCA (5, 10, or 25 mg/d for 17 days). Fecal and plasma specimens were collected at baseline (day 0) and on days 17 (end of dosing) and 37 (end of study). The fecal specimens were analyzed by shotgun meta-genomic sequencing. A Uniref90 high-stringency genomic analysis was used to assign specific genes to the taxonomic signature of bacteria whose abundance was associated with OCA. Male C57BL/6 mice were gavage fed daily with water, vehicle, or OCA (10 mg/kg) for 2 weeks. Small intestine luminal contents were collected by flushing with saline and fecal pellets were collected at baseline and day 14. Mouse samples were analyzed by 16S-tagged sequencing. Culture experiments were performed to determine the taxonomic-specific effects of bile acids and OCA on bacterial growth V体育安卓版. .

Results: Suppression of endogenous bile acid synthesis by OCA in subjects led to a reversible induction of gram-positive bacteria that are found in the small intestine and are components of the diet and oral microbiota V体育ios版. We found that bile acids decreased proliferation of these bacteria in minimum inhibitory concentration assays. In these organisms, there was an increase in the representation of microbial genomic pathways involved in DNA synthesis and amino acid metabolism with OCA treatment of subjects. Consistent with these findings, mice fed OCA had lower endogenous bile acid levels and an increased proportion of Firmicutes, specifically in the small intestine, compared with mice fed water or vehicle. .

Conclusions: In studying the effects of OCA in humans and mice, we found evidence for interactions between bile acids and features of the small intestinal microbiome. These findings indicate that farnesoid X receptor activation alters the intestinal microbiota and could provide opportunities for microbiome biomarker discovery or new approaches to engineering the human microbiome. ClinicalTrials. gov, NCT01933503. VSports最新版本.

Keywords: Gene Regulation; Genetics; Metabolism; Nuclear Hormone Receptor V体育平台登录. .

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: LA is a consultant for and has stock options in Intercept Pharmaceuticals. FB and JE are employees and shareholders of Intercept Pharmaceuticals. GDW and RMC receive research funding from Intercept Pharmaceuticals V体育官网入口. The remaining authors declare no competing interests.

VSports在线直播 - Figures

Figure 1.
Figure 1.
Correlation between plasma C4 levels and the relative abundance of Streptococcus thermophilus in response to OCA treatment. Linear and box and whisker plots of: (A,C) plasma C4 levels and (B,D) S. thermophilus relative abundance in the 10 mg OCA group. The correlation between plasma C4 levels and the relative abundance of S. thermophilus were highly significant (FDR = 2.30e-05) based on a time-dependent GEE model.
Figure 2:
Figure 2:
Genomic signature of the fecal microbiome associated with OCA administration. (A) A multidimensional scaling (MDS) plot of samples based on the Kendall rank correlation coefficient derived from 782 genes with a time-dependent effect in response to OCA administration based (repeated measure ANOVA, FDR<0.01). (B) Distribution of the 782 genes by bacterial taxonomy. (C) The abundance of a selected transposase (V8LYU6, from S. thermophilus) over time. (D) Out of 394 total transposases identified in the samples, 32 transposases had significant time-dependent responses to each of the three OCA doses (shown as log10 mean abundance and 95% confidence interval across samples). (E) ROC curves for transposases and plasma C4 (Red: transposase with highest AUC (0.917); Blue: transposase with lowest AUC (0.789); Black: plasma C4 levels (AUC = 0.828)).
Figure 3:
Figure 3:
Bacterial metabolic pathways associated with OCA administration. (A) 135 metabolic pathways were significantly associated with OCA administration (repeated measure ANOVA, FDR < 0.01), categorized by bacterial taxa. (B) MDS plot of samples based on the Kendall rank correlation coefficient derived from the 135 metabolic pathways that were significantly associated with OCA administration. (C) Heatmap of significantly altered metabolic pathways from three major bacterial species sorted by time and dose. Metabolic pathways identified by Metacyc annotations were grouped into five classes (indicated by color on the y-axis).
Figure 4.
Figure 4.
Minimal inhibitory concentrations (MICs) of the two Gram-position bacterial species most strongly associated with the use of OCA in response to two endogenous bile acids and OCA. (A) MICs of the species in response to treatment with the two dominant conjugated primary bile acids found in the human small intestine, glycochenodeoxycholic acid (GCDCA) and glycocholic acid (GCA), under both aerobic and anaerobic conditions. N=3 per measurement. Blue = Physiologically relevant concentrations of bile acids in the human small intestine. (B) MICs of the same bacterial taxa in response to treatment with OCA. N=3 per measurement. Blue = Estimated human small intestinal concentrations of OCA.
Figure 5.
Figure 5.
Effect of OCA administration on luminal bile acid concentrations in the murine small intestine and feces. Total (endogenous bile acids and OCA), total endogenous, total primary, and total secondary bile acids in the (A) lumen of the proximal small intestine; (B) lumen of the distal small intestine, and; (C) feces of mice following 14 days of gavage with either water (control, N=5), 0.5% methylcellulose (MC, N=10), or 0.5% methylcellulose with 10 mg/kg obeticholic acid (OCA, N=10). Mean±SE, *p<0.05, **p<0.01, ***p<0.001. Heatmaps of luminal bile acid concentrations in the proximal (D) and distal (E) small intestine.
Figure 6.
Figure 6.
Effect of OCA on the proximal and distal small intestinal (PSI and DSI, respectively), as well as the fecal, microbiota composition in mice based on 16S tagged sequencing following 14 days of gavage with water (control), 0.5% methylcellulose (MC), or 0.5% methylcellulose with 10 mg/kg obeticholic acid (OCA).
Figure 7:
Figure 7:
The power of the relative abundance of bacterial species to discriminate OCA treatment (day 16) vs. non-treatment (days 1 and 37) as assessed by logistic regression models. (A) The three species with the highest AUC values based on a ROC analysis of the three OCA doses. (B) AUC values based on a ROC analysis using the combination of any two of the three species with the highest AUC values. (C) AUC values based on separate ROC analyses for Day 1 vs. Day 16 and Day 37 vs. Day 16 based on logistic regression analysis. Species with high AUC values (AUC > 0.8) from at least one model are shown. The pseudo-validation AUCs were obtained by applying the logistic model derived from the Day 1 vs. Day 16 dataset (i.e., training set) to the Day 16 vs. Day 37 dataset (i.e., validation set).

References

    1. Derrien M, van Hylckama Vlieg JE. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol 2015;23:354–66. - PubMed
    1. van den Bogert B, Erkus O, Boekhorst J, et al. Diversity of human small intestinal Streptococcus and Veillonella populations. FEMS Microbiol Ecol 2013;85:376–88. - PubMed (VSports手机版)
    1. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957–63. - PMC - PubMed
    1. Schneider KM, Albers S, Trautwein C. Role of bile acids in the gut-liver axis. Journal of Hepatology 2018;68:1083–1085. - PubMed
    1. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 2015;17:500. - PubMed

Publication types

Substances (VSports最新版本)

Associated data